EUVIMEDEUVIMED entdecken
Crossref

Safety of Janus kinase inhibitors compared to biologic therapy in patients with inflammatory bowel disease

Gursimran S Kochhar, Himsikhar Khataniar, Parambir S Dulai, Aakash Desai

Intestinal Research · 07.05.2026

DOI: 10.5217/ir.2025.00232 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Intestinal Research, online erschienen am 07.05.2026. Verfasst von Gursimran S Kochhar und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, Hepatology and Nutrition, Allegheny Health Network, Pittsburgh, PA, USA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

Crohn diseaseJanus kinase inhibitorsTofacitinibUlcerative colitisUpadacitinib

Autor:innen und Institutionen

  • Division of Gastroenterology, Hepatology and Nutrition, Allegheny Health Network, Pittsburgh, PA, USA.
  • Department of Medicine, Allegheny Health Network, Pittsburgh, PA, USA.
  • Division of Gastroenterology, Hepatology and Nutrition, Northwestern University, Chicago, IL, USA.

Zitieren

APA

Kochhar, G. S., Khataniar, H., Dulai, P. S., & Desai, A. (2026). Safety of Janus kinase inhibitors compared to biologic therapy in patients with inflammatory bowel disease. Intestinal Research. https://doi.org/10.5217/ir.2025.00232

Vancouver

Kochhar GS, Khataniar H, Dulai PS, Desai A. Safety of Janus kinase inhibitors compared to biologic therapy in patients with inflammatory bowel disease. Intestinal Research. 2026. doi:10.5217/ir.2025.00232

BibTeX
@article{Kochhar2026,
  author = {Kochhar, Gursimran S and Khataniar, Himsikhar and Dulai, Parambir S and Desai, Aakash},
  title = {Safety of Janus kinase inhibitors compared to biologic therapy in patients with inflammatory bowel disease},
  journal = {Intestinal Research},
  year = {2026},
  doi = {10.5217/ir.2025.00232}
}
Kostenlos starten →